Skip to main content
Premium Trial:

Request an Annual Quote

Atossa Subsidiary NRLBH, BioVentive Ink Marketing Deal

NEW YORK (GenomeWeb) – Atossa Genetics announced today that its subsidiary, the National Reference Laboratory for Breast Health, and BioVentive have reached a deal to market and promote NRLBH's services.

NRLBH is a CLIA-registered laboratory based in Seattle that offers anatomic and clinical pathology services and molecular-based testing. BioVentive provides sales and marketing services to healthcare companies.

In a statement, Atossa President and CEO Steven Quay said that BioVentive's sales force is "highly regarded by the medical community," and that he anticipates the company will play "a vital role as the NRLBH develops and commercializes its testing services."

Atossa develops tests and other medical devices, as well as laboratory services and therapeutics aimed at breast cancer. Its lab services are being developed by NRLBH. BioVentive has a sales force of 85 who will offer NRLBH's services throughout the US, Quay added.

Financial and other terms of the deal were not disclosed.

Last week Atossa announced it submitted additional information to the US Food and Drug Administration related to its 510(k) submission for the ForeCYTE Breast Aspirator.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.